Private Advisor Group LLC decreased its position in shares of Stryker Co. (NYSE:SYK – Get Rating) by 10.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,522 shares of the medical technology company’s stock after selling 1,402 shares during the quarter. Private Advisor Group LLC’s holdings in Stryker were worth $792,339,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. MADDEN SECURITIES Corp acquired a new position in Stryker during the fourth quarter worth about $29,000. Align Wealth Management LLC acquired a new position in Stryker during the fourth quarter worth about $25,000. Hazlett Burt & Watson Inc. acquired a new position in Stryker during the third quarter worth about $41,000. Glassy Mountain Advisors Inc. acquired a new position in Stryker during the fourth quarter worth about $49,000. Finally, EWG Elevate Inc. acquired a new position in Stryker during the fourth quarter worth about $51,000. Institutional investors own 77.10% of the company’s stock.
Insiders Place Their Bets
In other Stryker news, insider James Andrew Pierce sold 400 shares of Stryker stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $277.88, for a total value of $111,152.00. Following the sale, the insider now owns 46,676 shares of the company’s stock, valued at $12,970,326.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Stryker news, insider James Andrew Pierce sold 400 shares of Stryker stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $277.88, for a total value of $111,152.00. Following the sale, the insider now owns 46,676 shares of the company’s stock, valued at $12,970,326.88. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 6,571 shares of Stryker stock in a transaction dated Wednesday, January 11th. The stock was sold at an average price of $257.69, for a total transaction of $1,693,280.99. Following the completion of the sale, the vice president now directly owns 9,264 shares in the company, valued at approximately $2,387,240.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 357,410 shares of company stock valued at $97,831,003. Company insiders own 6.50% of the company’s stock.
Stryker Trading Down 0.3 %
Stryker (NYSE:SYK – Get Rating) last released its quarterly earnings results on Tuesday, January 31st. The medical technology company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.16. Stryker had a return on equity of 22.39% and a net margin of 12.78%. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the prior year, the firm posted $2.71 EPS. Stryker’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, analysts predict that Stryker Co. will post 10.02 EPS for the current fiscal year.
Stryker Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be given a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.08%. The ex-dividend date is Thursday, March 30th. Stryker’s dividend payout ratio is 48.62%.
Wall Street Analysts Forecast Growth
Several brokerages have commented on SYK. Loop Capital boosted their target price on Stryker from $245.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, February 1st. Royal Bank of Canada upped their price objective on Stryker from $284.00 to $288.00 and gave the company an “outperform” rating in a research note on Wednesday, February 1st. Evercore ISI upped their price objective on Stryker to $265.00 in a research note on Tuesday, January 3rd. Wells Fargo & Company upped their price objective on Stryker from $281.00 to $285.00 and gave the company an “overweight” rating in a research note on Wednesday, February 1st. Finally, Truist Financial upped their price objective on Stryker from $257.00 to $275.00 and gave the company a “hold” rating in a research note on Wednesday, February 1st. Eight equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $270.79.
Stryker Profile
Stryker Corp. is a medical technology company, which engages in the provision of innovative products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery.
Read More
- Get a free copy of the StockNews.com research report on Stryker (SYK)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK – Get Rating).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
